Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study shows that IKZF1 and the protein IKAROS may play a role in the development of alopecia areata, based on findings from both mouse models and human scalp tissues.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

This article discusses the ISHRS's focus on research, education, and collegiality within hair loss treatment and reports no clinical results.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

In this animal study, hibiscus leaf simplicia ointment was found to protect red blood cell levels and promote better hair growth in UV-exposed rats, though it did not maintain normal skin histology; the ointment showed no significant acute dermal toxicity.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

This study suggests that the use of 5α-reductase inhibitors in men may be associated with macular abnormalities, characterized by cystoid changes and foveal cavitation, potentially progressing to more severe defects.

Inositol helped cure hair loss around rats' eyes and improved their growth.

This study observed a high incidence of hemangioma rubi on the scalp in older adults, which had not been previously reported in the literature.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

This study found that using senseviera hair tonic significantly increased hair density among women aged 19-25 who wear hijabs.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This study generated a pharmacophoric model for both isoforms of steroidal 5α-reductase using 6-azasteroids, providing a structural framework for designing new inhibitors.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

This review discusses indole-based bifunctional aldose reductase inhibitors and antioxidants for diabetic complications and chronic inflammation-related pathologies, but reports no new clinical results.

This article discusses the educational role of the ISHRS since its establishment in 1993, but reports no new research findings.

This article reports that the ISHRS has formed a committee to register hair restoration outcomes in patients with cicatricial alopecia and other hair diseases, without presenting new research findings.

This study suggests that using opioids along with 5αRI may reduce opioid use disorder risk in humans, supporting similar findings from animal studies.

This paper creatively examines whether the name "Janus" in Janus kinase inhibitors foreshadows their dual role in the treatment of dermatological conditions, drawing parallels to the Roman god Janus's dual nature and influence over beginnings and transitions.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

This study observed that patients with alopecia areata taking ritlecitinib reported higher satisfaction with hair growth after 24 and 48 weeks compared to those taking a placebo, aligning with improvements in hair growth noted by doctors.

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

In this study using a virtual screening approach, eriocitrin and silymarin were identified as potent flavonoid compounds that strongly and stably interacted with 5α-reductase type II, suggesting potential development as novel treatments for androgenic alopecia.

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.